Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.0
3.4
Journals
Life
Special Issues
Advancements in Heart Failure Research: 2nd Edition
share announcement

Advancements in Heart Failure Research: 2nd Edition

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 498

Special Issue Editors

Prof. Dr. Tzu-Hurng Cheng

E-Mail Website
Guest Editor
Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91, Xueshi Road, North District, Taichung City 404328, Taiwan
Interests: biochemistry; signal transduction; molecular cardiology; natural products; cardiovascular pharmacology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Ju-Chi Liu

E-Mail Website
Guest Editor
1. Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
2. Taipei Heart Institute, Taipei Medical University, Taipei, Taiwan
3. Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Interests: heart failure; arrythmia; coronary artery disease; hypertension
Special Issues, Collections and Topics in MDPI journals
Dr. Po-Yuan Chen

E-Mail Website
Guest Editor
Department of Biological Science and Technology, China Medical University, Taichung 406, Taiwan
Interests: biophysics; chemical engineering; biomedical engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure persists as a significant global health challenge despite strides in treatment. This Special Issue aims to comprehensively explore recent advancements in heart failure research, from its roots to innovative interventions. Essential to effective management is understanding the intricate mechanisms driving heart failure. Articles within this Special Issue delve into pathophysiological processes such as myocardial remodeling, neurohormonal activation, and genetic predispositions. Moreover, the Special Issue navigates emerging diagnostic modalities like novel biomarkers, advanced imaging techniques, and artificial intelligence applications, crucial for timely and accurate diagnosis.

Highlighting the latest therapeutic strategies, from pharmacological interventions to device-based therapies and surgical procedures, this Special Issue underscores precision medicine approaches, innovative drug therapies, and the role of cardiac devices like ventricular assist devices and cardiac transplantation. Managing heart failure alongside comorbidities poses unique challenges, addressed in discussions on strategies to tackle common issues like hypertension, diabetes, and chronic kidney disease. Fostering patient-centered care remains paramount, with a focus on holistic approaches, remote monitoring technologies, and strategies promoting self-care and treatment adherence.

Lastly, this Special Issue anticipates future trends, examining promising avenues like regenerative medicine and the integration of digital health technologies in personalized care. By bringing together cutting-edge research and insights from leading experts in the field, this Special Issue aims to advance our understanding of heart failure and pave the way for improved management strategies and patient outcomes.

We invite researchers and clinicians to contribute original research articles, reviews, and perspectives to this Special Issue, with the goal of fostering collaboration and driving innovation in the field of heart failure research.

Previous Special Issue: https://www.mdpi.com/journal/life/special_issues/V2ODCQFXF0.

Prof. Dr. Tzu-Hurng Cheng
Prof. Dr. Ju-Chi Liu
Dr. Po-Yuan Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiac remodeling
  • biomarkers
  • precision medicine
  • patient-centered care
  • therapeutic innovations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 1672 KB  
Article
Hibiscus syriacus L. Exhibits Cardioprotective Activity via Anti-Inflammatory and Antioxidant Mechanisms in an In Vitro Model of Heart Failure
by Hung-Hsin Chao, Tzu-Hurng Cheng, Chun-Chao Chen, Ju-Chi Liu, Jin-Jer Chen and Li-Chin Sung
Life 2025, 15(8), 1229; https://doi.org/10.3390/life15081229 - 3 Aug 2025
Viewed by 369
Abstract
Hibiscus syriacus L. (HS), native to Eastern and Southern Asia, has been traditionally used in Asian herbal medicine for its anticancer, antimicrobial, and anti-inflammatory properties. Despite these recognized bioactivities, its potential cardioprotective effects, particularly in the setting of heart failure (HF), remain largely [...] Read more.
Hibiscus syriacus L. (HS), native to Eastern and Southern Asia, has been traditionally used in Asian herbal medicine for its anticancer, antimicrobial, and anti-inflammatory properties. Despite these recognized bioactivities, its potential cardioprotective effects, particularly in the setting of heart failure (HF), remain largely unexplored. This study aimed to investigate the effects of HS extracts and its bioactive constituents on angiotensin II (Ang II)-induced cardiac injury using an in vitro model with H9c2 rat cardiomyocytes. Cells exposed to Ang II were pretreated with HS extracts, and assays were performed to assess cell viability, reactive oxygen species (ROS) generation, protein synthesis, and secretion of inflammatory mediators, including tumor necrosis factor-alpha, interleukin 1β (IL-1β), and interleukin 6 (IL-6), as well as chemokine (CCL20) and HF-related biomarkers, such as brain natriuretic peptide (BNP) and endothelin-1. The results demonstrated that HS extracts significantly and dose-dependently attenuated Ang II-induced ROS accumulation and suppressed the secretion of pro-inflammatory cytokines, chemokines, BNP, and endothelin-1. Additionally, HS and its purified components inhibited Ang II-induced protein synthesis, indicating anti-hypertrophic effects. Collectively, these findings highlight the antioxidative, anti-inflammatory, and antihypertrophic properties of HS in the context of Ang II-induced cardiac injury, suggesting that HS may represent a promising adjunctive therapeutic candidate for HF management. Further in vivo studies and mechanistic investigations are warranted to validate its clinical potential. Full article
(This article belongs to the Special Issue Advancements in Heart Failure Research: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop